Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Most people will recover from viruses like the flu, COVID, and RSV without medical care, but some patients might need a trip ...

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

A recent modification to the contract would have allowed Vaxart to invoice BARDA for the remaining $230 million or so for ...